GNRH1 and prostate carcinoma: SARM therapy as an adjuvant to androgen deprivation therapy in prostate cancer may protect against the adverse musculoskeletal, metabolic and neuro-cognitive impacts of hypogonadism induced by GnRH agonists and other therapies for prostate cancer, while at the same time inhibiting prostate cancer tissue proliferation and growth (Chisamore et al., 2016).